Trius 'Establishes' Key Endpoints for its Tedizolid Phase III Trial
By Staff Reports
Thursday, February 14, 2013
San Diego-based Trius Therapeutics Inc. said the results from its first pivotal Phase III study of tedizolid phosphate (TR-701) vs. linezolid (Zyvox) completed in 2011 (ESTABLISH 1), have been published in the Journal of the American Medical Association (JAMA).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.